Items Tagged ‘urothlial carcinoma’

June 8th, 2016

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer


The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Bladder cancer will be diagnosed in approximately 77,000 people in […]

View full entry

Tags: advanced, atezolizumab, Bladder Cancer, elderly, immunotherapy Tecentriq, News, smokers, Stage IV/Metastatic Bladder Cancer, urothlial carcinoma